Navigation Links
Alzheimer's Costs Could Explode by Mid-Century
Date:5/19/2010

Report anticipates U.S. bill of $20 trillion over next 40 years

WEDNESDAY, May 19 (HealthDay News) -- The number of Americans age 65 and older with Alzheimer's disease will more than double in the next 40 years, and the cumulative costs of caring for them between now and 2050 will exceed $20 trillion, a new report from the Alzheimer's Association finds.

"We know that Alzheimer's disease is not just 'a little memory loss' -- it is a national crisis that grows worse by the day," Harry Johns, president and CEO of the Alzheimer's Association, said in a news release issued Wednesday.

"Alzheimer's not only poses a significant threat to millions of families, but also drives tremendous costs for government programs like Medicare and Medicaid," he said.

The report, titled "Changing the Trajectory of Alzheimer's Disease: A National Imperative, predicts that the increase in Alzheimer's patients -- from 5.1 million today to 13.5 million in 2050 -- will raise total Alzheimer's costs by all payers from $172 billion in 2010 to more than $1 trillion in 2050.

Annual Medicare costs will soar more than 600 percent, from $88 billion today to $627 billion in 2050. Medicaid costs will rise from $34 billion to $178 billion by 2050, the report says.

One reason why costs will balloon by mid-century is that almost half of all Alzheimer's patients will be in the severe stage of the disease by then, requiring intensive -- and expensive - care, the report noted.

The predictions were based on a model developed by the Lewin Group for the Alzheimer's Association that assumed no cure would be found for the disease.

But Johns said treatment breakthroughs could dramatically alter the dire forecast.

"While the ultimate goal is a treatment that can completely prevent or cure Alzheimer's, we can now see that even modest improvements can have a huge impact," Johns said.

A discovery that postpones disease onset by five years and starts showing an effect in 2015 would reduce the population of Americans age 65 and older with Alzheimer's from 5.6 million to 4 million in 2020, the report said.

The association said such a breakthrough would result in the following:

  • 43 percent of the 13.5 million Americans who would have been expected to have the condition in 2050 would be free of it.
  • Many fewer people would be in the severe stage by 2050 -- 3.5 million instead of the expected 6.5 million.
  • The savings to Medicare and Medicaid would be substantial. Compared to current trends, annual Medicare savings would be $33 billion in 2020 and $283 billion by mid-century, while savings for Medicaid would grow from $9 billion in 2020 to $79 billion in 2050.

Increased government funding of Alzheimer's research should be a priority, Johns said.

"Given the magnitude and the impact of this disease, the government's response to this burgeoning crisis has been stunningly neglectful," said Johns. "For the human effects and the country's fiscal future, we must change the trajectory of the Alzheimer crisis."

More information

For more about Alzheimer's disease, visit the U.S. National Library of Medicine.



-- Margaret Steele



SOURCE: Alzheimer's Association, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Study shows costs and benefits of testosterone in birds
2. U.S. Cancer Costs Double in Two Decades
3. Medical costs of cancer have nearly doubled over the past 2 decades
4. PCMA: New Legislation Would Increase Prescription Drug Costs, Limit Access
5. Urgent Nuclear Stress Test Lab Costs Reductions for Physician Practices in Need
6. Imaging costs rising faster than total cancer care for Medicare
7. Use and costs of diagnostic imaging increasing for patients with cancer
8. Imaging Costs Soar for Medicare Cancer Patients
9. Domestic violence victims have higher health costs for years after abuse ends
10. Hospital Cost Shifting Adds to Auto Injury Claim Costs
11. HD Telepresence Gets More Affordable for SMBs: XVD Espresso HD Delivers Higher Performance at Lower Costs than Traditional Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: